114 related articles for article (PubMed ID: 38679213)
1. Development of a topical treatment for tegumentary leishmaniasis using 8-hydroxyquinoline.
Rezende Ribeiro N; Magno Oliveira Santos L; Silva Costa S; Kei Myasaki C; Pagliara Lage D; Tamietti Martins V; Cristiane Fortes De Brito R; Chaves Freire L; Maria Ravena Severino Carvalho A; Victor Serafim Brigido B; José Alves R; Antonio Ferraz Coelho E; Mendes Roatt B; Menezes-Souza D; Costa Duarte M
Eur J Pharm Biopharm; 2024 Jun; 199():114306. PubMed ID: 38679213
[TBL] [Abstract][Full Text] [Related]
2. An 8-hydroxyquinoline-containing polymeric micelle system is effective for the treatment of murine tegumentary leishmaniasis.
Lage LM; Barichello JM; Lage DP; Mendonça DV; Carvalho AM; Rodrigues MR; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Coelho EA; Duarte MC
Parasitol Res; 2016 Nov; 115(11):4083-4095. PubMed ID: 27365053
[TBL] [Abstract][Full Text] [Related]
3. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
[TBL] [Abstract][Full Text] [Related]
4. Treatment of murine visceral leishmaniasis using an 8-hydroxyquinoline-containing polymeric micelle system.
Duarte MC; Lage LM; Lage DP; Martins VT; Carvalho AM; Roatt BM; Menezes-Souza D; Tavares CA; Alves RJ; Barichello JM; Coelho EA
Parasitol Int; 2016 Dec; 65(6 Pt A):728-736. PubMed ID: 27425599
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of nanoemulsion with Pterodon emarginatus Vogel oleoresin for topical treatment of cutaneous leishmaniasis.
Kawakami MYM; Zamora LO; Araújo RS; Fernandes CP; Ricotta TQN; de Oliveira LG; Queiroz-Junior CM; Fernandes AP; da Conceição EC; Ferreira LAM; Barros ALB; Aguiar MG; Oliveira AEMFM
Biomed Pharmacother; 2021 Feb; 134():111109. PubMed ID: 33341050
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
[TBL] [Abstract][Full Text] [Related]
7. Poloxamer 407 (Pluronic(®) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis.
Mendonça DV; Lage LM; Lage DP; Chávez-Fumagalli MA; Ludolf F; Roatt BM; Menezes-Souza D; Faraco AA; Castilho RO; Tavares CA; Barichello JM; Duarte MC; Coelho EA
Exp Parasitol; 2016 Oct; 169():34-42. PubMed ID: 27427166
[TBL] [Abstract][Full Text] [Related]
8. S-nitrosoglutathione (GSNO) is cytotoxic to intracellular amastigotes and promotes healing of topically treated Leishmania major or Leishmania braziliensis skin lesions.
Costa IS; de Souza GF; de Oliveira MG; Abrahamsohn Ide A
J Antimicrob Chemother; 2013 Nov; 68(11):2561-8. PubMed ID: 23788476
[TBL] [Abstract][Full Text] [Related]
9. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
Moosavian SA; Fallah M; Jaafari MR
Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.
Godinho JL; Simas-Rodrigues C; Silva R; Ürmenyi TP; de Souza W; Rodrigues JC
Int J Antimicrob Agents; 2012 Apr; 39(4):326-31. PubMed ID: 22226653
[TBL] [Abstract][Full Text] [Related]
11. Topical treatment of L. major infected BALB/c mice with a novel diselenide chitosan hydrogel formulation.
Schwartz J; Moreno E; Fernández C; Navarro-Blasco I; Nguewa PA; Palop JA; Irache JM; Sanmartín C; Espuelas S
Eur J Pharm Sci; 2014 Oct; 62():309-16. PubMed ID: 24964292
[TBL] [Abstract][Full Text] [Related]
12. Topical treatment with nanoliposomal Amphotericin B reduces early lesion growth but fails to induce cure in an experimental model of cutaneous leishmaniasis caused by Leishmania mexicana.
Varikuti S; Oghumu S; Saljoughian N; Pioso MS; Sedmak BE; Khamesipour A; Satoskar AR
Acta Trop; 2017 Sep; 173():102-108. PubMed ID: 28602835
[TBL] [Abstract][Full Text] [Related]
13. Leishmanicidal potentials of
Sharifi F; Sharififar F; Pournamdari M; Ansari M; Tavakoli Oliaee R; Bamorovat M; Khosravi A; Keyhani AR; Salarkia E; Mortazaeizdeh A; Dabiri S; Khamesipour A; Sharifi I
J Med Microbiol; 2021 Jun; 70(6):. PubMed ID: 34115583
[No Abstract] [Full Text] [Related]
14. Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis.
Neira LF; Mantilla JC; Escobar P
J Antimicrob Chemother; 2019 Jun; 74(6):1634-1641. PubMed ID: 30815688
[TBL] [Abstract][Full Text] [Related]
15. Lipid nanoparticles for amphotericin delivery in the treatment of American tegumentary leishmaniasis.
de Souza RM; Maranhão RC; Tavares ER; Filippin-Monteiro FB; Nicodemo AC; Morikawa AT; Kanashiro EHY; Amato VS
Drug Deliv Transl Res; 2020 Apr; 10(2):403-412. PubMed ID: 31701487
[TBL] [Abstract][Full Text] [Related]
16. Nitric-oxide releasing chitosan nanoparticles towards effective treatment of cutaneous leishmaniasis.
Cabral FV; Pelegrino MT; Seabra AB; Ribeiro MS
Nitric Oxide; 2021 Sep; 113-114():31-38. PubMed ID: 33940194
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of the local or oral delivery of the novel naphthopterocarpanquinone LQB-118 against cutaneous leishmaniasis.
da Cunha-Júnior EF; Pacienza-Lima W; Ribeiro GA; Netto CD; do Canto-Cavalheiro MM; da Silva AJ; Costa PR; Rossi-Bergmann B; Torres-Santos EC
J Antimicrob Chemother; 2011 Jul; 66(7):1555-9. PubMed ID: 21531758
[TBL] [Abstract][Full Text] [Related]
18. Exploring drug repositioning for leishmaniasis treatment: Ivermectin plus polymeric micelles induce immunological response and protection against tegumentary leishmaniasis.
Freitas CS; Lage DP; Machado AS; Vale DL; Martins VT; Cardoso JMO; Oliveira-da-Silva JA; Reis TAR; Tavares GSV; Ramos FF; Ludolf F; Pereira IAG; Bandeira RS; Fujiwara RT; Bueno LL; Roatt BM; Chávez-Fumagalli MA; Coelho EAF
Cytokine; 2023 Apr; 164():156143. PubMed ID: 36774730
[TBL] [Abstract][Full Text] [Related]
19. Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasis.
Jesus MM; Lage DP; Vale DL; Freitas CS; Pimenta BL; Moreira GJL; Ramos FF; Pereira IAG; Bandeira RS; Ludolf F; Tavares GSV; Galdino AS; Duarte MC; Menezes-Souza D; Chávez-Fumagalli MA; Teixeira AL; Gonçalves DU; Roatt BM; Christodoulides M; Martins VT; Coelho EAF
Parasitol Res; 2023 Dec; 122(12):2917-2931. PubMed ID: 37768367
[TBL] [Abstract][Full Text] [Related]
20. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions.
Schwartz J; Moreno E; Calvo A; Blanco L; Fernández-Rubio C; Sanmartín C; Nguewa P; Irache JM; Larrea E; Espuelas S
J Dermatol Sci; 2018 Oct; 92(1):78-88. PubMed ID: 30037731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
